Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 3/20 | 0.85 |
| ▸ | KDM6B | O15054 | 1/20 | 0.85 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | KDM5A | P29375 | 1/20 | 0.85 |
| ▸ | BLVRB | P30043 | 1/20 | 0.85 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.85 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.85 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deferasirox SCHEMBL61756 | 0.92 | KDM4A (1.00) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| Deferasirox SCHEMBL29381781 | 0.92 | KDM4A (1.00) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL5843247 | 0.85 | KDM4A (0.81) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL20080980 | 0.85 | KDM4A (0.85) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL25697702 | 0.84 | KDM4A (0.80) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL21232846 | 0.84 | KDM4A (0.76) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL22184113 | 0.84 | KDM4A (0.80) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL19722958 | 0.83 | KDM4A (0.78) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL5842285 | 0.83 | KDM4A (0.81) | KDM4AKDM6BABCC4ABCB11KDM5A | |
| SCHEMBL20620461 | 0.82 | KDM4A (0.80) | KDM4AKDM6BABCC4ABCB11KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074815-B2 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | NOVARTIS AG (CH) | 2006-07-11 | — | — | US | claimed |
| US-20050080120-A1 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | NOVARTIS AG (CH) | 2005-04-14 | — | — | US | claimed |
| EP-1443924-A1 | 4-[3,5-BIS-(2-HYDROXY-PHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID DERIVATIVES FOR TREATING AN EXCESS OF METAL IN THE BODY | Novartis AG (CH) | 2004-08-11 | — | — | EP | claimed |
| WO-2003039541-A1 | 4-[3,5-BIS-(2-HYDROXY-PHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID DERIVATIVES FOR TREATING AN EXCESS OF METAL IN THE BODY | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | claimed |
| US-7074815-B2 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | NOVARTIS AG (CH) | 2006-07-11 | — | — | US | disclosed |
| US-20050080120-A1 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | NOVARTIS AG (CH) | 2005-04-14 | — | — | US | disclosed |
| EP-1443924-A1 | 4-[3,5-BIS-(2-HYDROXY-PHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID DERIVATIVES FOR TREATING AN EXCESS OF METAL IN THE BODY | Novartis AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003039541-A1 | 4-[3,5-BIS-(2-HYDROXY-PHENYL)-[1,2,4]TRIAZOL-1-YL]-BENZOIC ACID DERIVATIVES FOR TREATING AN EXCESS OF METAL IN THE BODY | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080120-A1 | 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body | PAH, P4HA1, CYP27B1 | KDM4A 1030/4885KDM6B 1348/4885ABCC4 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.